Pharma Journalist -

Variant Bio, a genomics-driven drug discovery company, announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.…
Read More...

Tempest Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule,…
Read More...

Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), and Fortress Biotech, Inc. ("Fortress")…
Read More...

Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases,…
Read More...

GSK plc announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC)…
Read More...

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultrarare genetic diseases, announced that…
Read More...

GSK plc announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on…
Read More...

LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention, announced that it has signed a term sheet to…
Read More...

Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs announced that it has entered…
Read More...

Astellas Pharma Inc. announced that China's National Medical Products Administration (NMPA) has approved VYLOY™ (zolbetuximab), in combination with fluoropyrimidine- and…
Read More...